| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $18.5M | — | -17.5% |
| SG&A Expense | $8.8M | — | +113.2% |
| Operating Income | -$27.3M | — | -2.8% |
| Net Income | -$23.5M | — | +1.5% |
| EPS (Basic) | -$0.50 | — | +29.6% |
| EPS (Diluted) | -$0.50 | — | +29.6% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $45.2M | -39.9% | +51.2% |
| Short-term Investments | $394.8M | +32.3% | +87.2% |
| Current Assets | $448.5M | +17.6% | +83.6% |
| Total Assets | $452.7M | +17.5% | +84.1% |
| Current Liabilities | $14.6M | -6.0% | +39.0% |
| Total Liabilities | $14.9M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$20.2M | — | +10.9% |
| Capital Expenditures | $437K | — | +1356.7% |
| Investing Cash Flow | -$97.1M | — | -3109.8% |
| Financing Cash Flow | $87.4M | — | — |
| Free Cash Flow | -$20.6M | — | +9.1% |
| +42.3% |
| Stockholders' Equity | $437.8M | +18.6% | +85.9% |